New growth engine helps Ferraris plan route for success
This article was originally published in Clinica
Executive Summary
At first glance, UK company Ferraris looks like a company with more breadth than depth of focus, and its recent acquisition of test control solution maker Bionostics could be seen as an act of further diversification. However, on closer inspection it is possible to identify a new strategic direction informing its current activities. Clinica's Eleanor Malone met the management to find out more.